Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

Covalent binders in drug discovery.

Vasudevan A, Argiriadi MA, Baranczak A, Friedman MM, Gavrilyuk J, Hobson AD, Hulce JJ, Osman S, Wilson NS.

Prog Med Chem. 2019;58:1-62. doi: 10.1016/bs.pmch.2018.12.002. Epub 2019 Mar 11.

PMID:
30879472
2.

Merits and Pitfalls in the Characterization of Covalent Inhibitors of Bruton's Tyrosine Kinase.

Harris CM, Foley SE, Goedken ER, Michalak M, Murdock S, Wilson NS.

SLAS Discov. 2018 Dec;23(10):1040-1050. doi: 10.1177/2472555218787445. Epub 2018 Jul 10.

PMID:
29991334
3.

Selective FcγR Co-engagement on APCs Modulates the Activity of Therapeutic Antibodies Targeting T Cell Antigens.

Waight JD, Chand D, Dietrich S, Gombos R, Horn T, Gonzalez AM, Manrique M, Swiech L, Morin B, Brittsan C, Tanne A, Akpeng B, Croker BA, Buell JS, Stein R, Savitsky DA, Wilson NS.

Cancer Cell. 2018 Jun 11;33(6):1033-1047.e5. doi: 10.1016/j.ccell.2018.05.005.

4.

Toxicological and pharmacological assessment of AGEN1884, a novel human IgG1 anti-CTLA-4 antibody.

Gombos RB, Gonzalez A, Manrique M, Chand D, Savitsky D, Morin B, Breous-Nystrom E, Dupont C, Ward RA, Mundt C, Duckless B, Tang H, Findeis MA, Schuster A, Waight JD, Underwood D, Clarke C, Ritter G, Merghoub T, Schaer D, Wolchok JD, van Dijk M, Buell JS, Cuillerot JM, Stein R, Drouin EE, Wilson NS.

PLoS One. 2018 Apr 4;13(4):e0191926. doi: 10.1371/journal.pone.0191926. eCollection 2018.

5.

Harnessing co-stimulatory TNF receptors for cancer immunotherapy: Current approaches and future opportunities.

Waight JD, Gombos RB, Wilson NS.

Hum Antibodies. 2017;25(3-4):87-109. doi: 10.3233/HAB-160308. Review.

PMID:
28085016
6.

Correction: Gene Expression Ratios Lead to Accurate and Translatable Predictors of DR5 Agonism across Multiple Tumor Lineages.

Reddy A, Growney JD, Wilson NS, Emery CM, Johnson JA, Ward R, Monaco KA, Korn J, Monahan JE, Stump MD, Mapa FA, Wilson CJ, Steiger J, Ledell J, Rickles RJ, Myer VE, Ettenberg SA, Schlegel R, Sellers WR, Huet HA, Lehár J.

PLoS One. 2016 Jan 5;11(1):e0146635. doi: 10.1371/journal.pone.0146635. eCollection 2016. No abstract available.

7.

Gene Expression Ratios Lead to Accurate and Translatable Predictors of DR5 Agonism across Multiple Tumor Lineages.

Reddy A, Growney JD, Wilson NS, Emery CM, Johnson JA, Ward R, Monaco KA, Korn J, Monahan JE, Stump MD, Mapa FA, Wilson CJ, Steiger J, Ledell J, Rickles RJ, Myer VE, Ettenberg SA, Schlegel R, Sellers WR, Huet HA, Lehár J.

PLoS One. 2015 Sep 17;10(9):e0138486. doi: 10.1371/journal.pone.0138486. eCollection 2015. Erratum in: PLoS One. 2016;11(1):e0146635.

8.

Response to comment on "cutting edge: epigenetic regulation of Foxp3 defines a stable population of CD4+ regulatory T cells in tumors from mice and humans".

Waight JD, Hofmeister R, Wilson NS.

J Immunol. 2015 Apr 15;194(8):3533-4. doi: 10.4049/jimmunol.1500367. No abstract available.

9.

Cutting edge: epigenetic regulation of Foxp3 defines a stable population of CD4+ regulatory T cells in tumors from mice and humans.

Waight JD, Takai S, Marelli B, Qin G, Hance KW, Zhang D, Tighe R, Lan Y, Lo KM, Sabzevari H, Hofmeister R, Wilson NS.

J Immunol. 2015 Feb 1;194(3):878-82. doi: 10.4049/jimmunol.1402725. Epub 2014 Dec 29.

10.

Validation of the Maryland Aggregate Pathology Index (MAPI), a pre-implantation scoring system that predicts graft outcome.

Philosophe B, Malat GE, Soundararajan S, Barth RN, Manitpisikul W, Wilson NS, Ranganna K, Drachenberg CB, Papadimitriou JC, Neuman BP, Munivenkatappa RB.

Clin Transplant. 2014 Aug;28(8):897-905. doi: 10.1111/ctr.12400. Epub 2014 Jul 8.

PMID:
24931144
11.

OX40 engagement depletes intratumoral Tregs via activating FcγRs, leading to antitumor efficacy.

Bulliard Y, Jolicoeur R, Zhang J, Dranoff G, Wilson NS, Brogdon JL.

Immunol Cell Biol. 2014 Jul;92(6):475-80. doi: 10.1038/icb.2014.26. Epub 2014 Apr 15.

PMID:
24732076
12.

Inflammasome-dependent and -independent IL-18 production mediates immunity to the ISCOMATRIX adjuvant.

Wilson NS, Duewell P, Yang B, Li Y, Marsters S, Koernig S, Latz E, Maraskovsky E, Morelli AB, Schnurr M, Ashkenazi A.

J Immunol. 2014 Apr 1;192(7):3259-68. doi: 10.4049/jimmunol.1302011. Epub 2014 Mar 7.

13.

Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies.

Bulliard Y, Jolicoeur R, Windman M, Rue SM, Ettenberg S, Knee DA, Wilson NS, Dranoff G, Brogdon JL.

J Exp Med. 2013 Aug 26;210(9):1685-93. doi: 10.1084/jem.20130573. Epub 2013 Jul 29.

14.

Host genetic background impacts modulation of the TLR4 pathway by RON in tissue-associated macrophages.

Chaudhuri A, Wilson NS, Yang B, Paler Martinez A, Liu J, Zhu C, Bricker N, Couto S, Modrusan Z, French D, Cupp J, Ashkenazi A.

Immunol Cell Biol. 2013 Aug;91(7):451-60. doi: 10.1038/icb.2013.27. Epub 2013 Jul 2.

15.

Proapoptotic activation of death receptor 5 on tumor endothelial cells disrupts the vasculature and reduces tumor growth.

Wilson NS, Yang A, Yang B, Couto S, Stern H, Gogineni A, Pitti R, Marsters S, Weimer RM, Singh M, Ashkenazi A.

Cancer Cell. 2012 Jul 10;22(1):80-90. doi: 10.1016/j.ccr.2012.05.014.

16.

ISCOMATRIX vaccines mediate CD8+ T-cell cross-priming by a MyD88-dependent signaling pathway.

Wilson NS, Yang B, Morelli AB, Koernig S, Yang A, Loeser S, Airey D, Provan L, Hass P, Braley H, Couto S, Drane D, Boyle J, Belz GT, Ashkenazi A, Maraskovsky E.

Immunol Cell Biol. 2012 May;90(5):540-52. doi: 10.1038/icb.2011.71. Epub 2011 Sep 6.

17.

An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells.

Wilson NS, Yang B, Yang A, Loeser S, Marsters S, Lawrence D, Li Y, Pitti R, Totpal K, Yee S, Ross S, Vernes JM, Lu Y, Adams C, Offringa R, Kelley B, Hymowitz S, Daniel D, Meng G, Ashkenazi A.

Cancer Cell. 2011 Jan 18;19(1):101-13. doi: 10.1016/j.ccr.2010.11.012.

18.

Proapoptotic DR4 and DR5 signaling in cancer cells: toward clinical translation.

Yang A, Wilson NS, Ashkenazi A.

Curr Opin Cell Biol. 2010 Dec;22(6):837-44. doi: 10.1016/j.ceb.2010.08.001. Epub 2010 Aug 31. Review.

PMID:
20813513
19.

Immunosuppressive agents as risk factors for BK virus nephropathy: an overview and update.

Manitpisitkul W, Wilson NS, Haririan A.

Expert Opin Drug Saf. 2010 Nov;9(6):959-69. doi: 10.1517/14740338.2010.495714. Review.

PMID:
20521865
20.

Rescue therapy for acute antibody mediated rejection with a proteosome inhibitor after kidney transplantation.

Manitpisitkul W, Wilson NS, Philosophe B, Cooper M, Drachenberg C, Kukuruga D, Nogueira J, Haririan A.

Clin Transpl. 2010:421-8. No abstract available.

PMID:
21698839
21.

Hyperkalemia-induced paralysis.

Wilson NS, Hudson JQ, Cox Z, King T, Finch CK.

Pharmacotherapy. 2009 Oct;29(10):1270-2. doi: 10.1592/phco.29.10.1270.

PMID:
19792996
22.

Development of prophylactic and therapeutic vaccines using the ISCOMATRIX adjuvant.

Maraskovsky E, Schnurr M, Wilson NS, Robson NC, Boyle J, Drane D.

Immunol Cell Biol. 2009 Jul;87(5):371-6. doi: 10.1038/icb.2009.21. Epub 2009 Apr 21. Review.

PMID:
19381160
23.

Death receptor signal transducers: nodes of coordination in immune signaling networks.

Wilson NS, Dixit V, Ashkenazi A.

Nat Immunol. 2009 Apr;10(4):348-55. doi: 10.1038/ni.1714. Epub 2009 Mar 19. Review.

PMID:
19295631
24.

Differential MHC class II synthesis and ubiquitination confers distinct antigen-presenting properties on conventional and plasmacytoid dendritic cells.

Young LJ, Wilson NS, Schnorrer P, Proietto A, ten Broeke T, Matsuki Y, Mount AM, Belz GT, O'Keeffe M, Ohmura-Hoshino M, Ishido S, Stoorvogel W, Heath WR, Shortman K, Villadangos JA.

Nat Immunol. 2008 Nov;9(11):1244-52. doi: 10.1038/ni.1665. Epub 2008 Oct 12.

PMID:
18849989
25.

Dendritic cells: driving the differentiation programme of T cells in viral infections.

Masson F, Mount AM, Wilson NS, Belz GT.

Immunol Cell Biol. 2008 May-Jun;86(4):333-42. doi: 10.1038/icb.2008.15. Epub 2008 Mar 18. Review.

PMID:
18347609
26.

Tumor necrosis factor: renaissance as a cancer therapeutic?

Daniel D, Wilson NS.

Curr Cancer Drug Targets. 2008 Mar;8(2):124-31. Review.

PMID:
18336195
27.

Construction and validation of an automated flow hydrogenation instrument for application in high-throughput organic chemistry.

Clapham B, Wilson NS, Michmerhuizen MJ, Blanchard DP, Dingle DM, Nemcek TA, Pan JY, Sauer DR.

J Comb Chem. 2008 Jan-Feb;10(1):88-93. Epub 2007 Dec 21.

PMID:
18095655
28.

Normal proportion and expression of maturation markers in migratory dendritic cells in the absence of germs or Toll-like receptor signaling.

Wilson NS, Young LJ, Kupresanin F, Naik SH, Vremec D, Heath WR, Akira S, Shortman K, Boyle J, Maraskovsky E, Belz GT, Villadangos JA.

Immunol Cell Biol. 2008 Feb;86(2):200-5. Epub 2007 Nov 20.

PMID:
18026177
29.

Dendritic cell preactivation impairs MHC class II presentation of vaccines and endogenous viral antigens.

Young LJ, Wilson NS, Schnorrer P, Mount A, Lundie RJ, La Gruta NL, Crabb BS, Belz GT, Heath WR, Villadangos JA.

Proc Natl Acad Sci U S A. 2007 Nov 6;104(45):17753-8. Epub 2007 Oct 31.

30.

Hit-to-lead studies on benzimidazole inhibitors of ITK: discovery of a novel class of kinase inhibitors.

Snow RJ, Abeywardane A, Campbell S, Lord J, Kashem MA, Khine HH, King J, Kowalski JA, Pullen SS, Roma T, Roth GP, Sarko CR, Wilson NS, Winters MP, Wolak JP, Cywin CL.

Bioorg Med Chem Lett. 2007 Jul 1;17(13):3660-5. Epub 2007 Apr 25.

PMID:
17499505
31.

Cognate CD4+ help elicited by resting dendritic cells does not impair the induction of peripheral tolerance in CD8+ T cells.

Steptoe RJ, Ritchie JM, Wilson NS, Villadangos JA, Lew AM, Harrison LC.

J Immunol. 2007 Feb 15;178(4):2094-103.

32.

Shaping naive and memory CD8+ T cell responses in pathogen infections through antigen presentation.

Belz GT, Wilson NS, Kupresanin F, Mount AM, Smith CM.

Adv Exp Med Biol. 2007;590:31-42. Review. No abstract available.

PMID:
17191375
33.

The dominant role of CD8+ dendritic cells in cross-presentation is not dictated by antigen capture.

Schnorrer P, Behrens GM, Wilson NS, Pooley JL, Smith CM, El-Sukkari D, Davey G, Kupresanin F, Li M, Maraskovsky E, Belz GT, Carbone FR, Shortman K, Heath WR, Villadangos JA.

Proc Natl Acad Sci U S A. 2006 Jul 11;103(28):10729-34. Epub 2006 Jun 28.

34.

Systemic activation of dendritic cells by Toll-like receptor ligands or malaria infection impairs cross-presentation and antiviral immunity.

Wilson NS, Behrens GM, Lundie RJ, Smith CM, Waithman J, Young L, Forehan SP, Mount A, Steptoe RJ, Shortman KD, de Koning-Ward TF, Belz GT, Carbone FR, Crabb BS, Heath WR, Villadangos JA.

Nat Immunol. 2006 Feb;7(2):165-72. Epub 2006 Jan 15.

PMID:
16415871
35.

Bone marrow-derived cells expand memory CD8+ T cells in response to viral infections of the lung and skin.

Belz GT, Wilson NS, Smith CM, Mount AM, Carbone FR, Heath WR.

Eur J Immunol. 2006 Feb;36(2):327-35.

36.

Control of MHC class II antigen presentation in dendritic cells: a balance between creative and destructive forces.

Villadangos JA, Schnorrer P, Wilson NS.

Immunol Rev. 2005 Oct;207:191-205. Review.

PMID:
16181337
37.

Cutting edge: generation of splenic CD8+ and CD8- dendritic cell equivalents in Fms-like tyrosine kinase 3 ligand bone marrow cultures.

Naik SH, Proietto AI, Wilson NS, Dakic A, Schnorrer P, Fuchsberger M, Lahoud MH, O'Keeffe M, Shao QX, Chen WF, Villadangos JA, Shortman K, Wu L.

J Immunol. 2005 Jun 1;174(11):6592-7.

39.

Cognate CD4(+) T cell licensing of dendritic cells in CD8(+) T cell immunity.

Smith CM, Wilson NS, Waithman J, Villadangos JA, Carbone FR, Heath WR, Belz GT.

Nat Immunol. 2004 Nov;5(11):1143-8. Epub 2004 Oct 10.

PMID:
15475958
40.

Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens.

Heath WR, Belz GT, Behrens GM, Smith CM, Forehan SP, Parish IA, Davey GM, Wilson NS, Carbone FR, Villadangos JA.

Immunol Rev. 2004 Jun;199:9-26. Review.

PMID:
15233723
41.

Lymphoid organ dendritic cells: beyond the Langerhans cells paradigm.

Wilson NS, Villadangos JA.

Immunol Cell Biol. 2004 Feb;82(1):91-8.

PMID:
14984600
42.

Column selectivity in reversed-phase liquid chromatography. VI. Columns with embedded or end-capping polar groups.

Wilson NS, Gilroy J, Dolan JW, Snyder LR.

J Chromatogr A. 2004 Feb 13;1026(1-2):91-100.

PMID:
14763736
43.

The protease inhibitor cystatin C is differentially expressed among dendritic cell populations, but does not control antigen presentation.

El-Sukkari D, Wilson NS, Hakansson K, Steptoe RJ, Grubb A, Shortman K, Villadangos JA.

J Immunol. 2003 Nov 15;171(10):5003-11.

45.

Most lymphoid organ dendritic cell types are phenotypically and functionally immature.

Wilson NS, El-Sukkari D, Belz GT, Smith CM, Steptoe RJ, Heath WR, Shortman K, Villadangos JA.

Blood. 2003 Sep 15;102(6):2187-94. Epub 2003 Jun 5.

PMID:
12791652
46.

Cutting edge: conventional CD8 alpha+ dendritic cells are preferentially involved in CTL priming after footpad infection with herpes simplex virus-1.

Smith CM, Belz GT, Wilson NS, Villadangos JA, Shortman K, Carbone FR, Heath WR.

J Immunol. 2003 May 1;170(9):4437-40.

47.

Recent trends in microwave-assisted synthesis.

Wilson NS, Roth GP.

Curr Opin Drug Discov Devel. 2002 Jul;5(4):620-9. Review.

PMID:
12197320
48.

Column selectivity in reversed-phase liquid chromatography III. The physico-chemical basis of selectivity.

Wilson NS, Dolan JW, Snyder LR, Carr PW, Sander LC.

J Chromatogr A. 2002 Jul 5;961(2):217-36.

PMID:
12184620
49.

Column selectivity in reversed-phase liquid chromatography II. Effect of a change in conditions.

Wilson NS, Nelson MD, Dolan JW, Snyder LR, Carr PW.

J Chromatogr A. 2002 Jul 5;961(2):195-215.

PMID:
12184619
50.

Column selectivity in reversed-phase liquid chromatography I. A general quantitative relationship.

Wilson NS, Nelson MD, Dolan JW, Snyder LR, Wolcott RG, Carr PW.

J Chromatogr A. 2002 Jul 5;961(2):171-93.

PMID:
12184618

Supplemental Content

Loading ...
Support Center